Research Article

Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic Index Score

Yuting Pan¹,², Hanyan Si¹, Ru Jia¹, Guochao Deng¹,², Huan Yan¹, Mengjia Fan¹, Miaomiao Gou¹, Shiyun Chen¹,², Nan Zhang¹,², Yue Shi¹, Niansong Qian³,⁴ and Guanghai Dai²

¹Medical Oncology Department, The First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing 100853, China
²Chinese People’s Liberation Army Medical School, Beijing 100853, China
³The Hainan Medical Center, Chinese PLA General Hospital, Sanya 572000, China
⁴The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510220, Guangdong Province, China

Correspondence should be addressed to Niansong Qian; kyotomed@foxmail.com and Guanghai Dai; daigh301@vip.sina.com

Received 5 November 2021; Revised 20 January 2022; Accepted 22 February 2022; Published 17 March 2022

Academic Editor: Faisal Raza

Copyright © 2022 Yuting Pan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The application of immunotherapy is gradually increasing in advanced bile tract carcinoma (BTC), but only some patients could benefit from it. Validated biomarkers can screen out the beneficiaries. Therefore, the objective of this research is aimed at exploring the predictive value of lung immune prognostic index (LIPI) in advanced BTC patients receiving immunotherapy.

Methods. This study was conducted on 110 BTC patients. The cut-off value of the derived neutrophil-to-lymphocyte (dNLR) ratio was obtained by the ROC curves to predict the tumor progression rate at the 6th month. The high levels of dNLR (≥ the cut-off value) and lactate dehydrogenase (≥ the upper limit of normal) were considered to be two risk factors for LIPI. Based on these two risk factors, patients were categorized into 3 groups based on risk factors: 0 for the good group, 1 for the intermediate group, and 2 for the poor group. Due to the limited number of patients in the poor group, it was integrated into the intermediate group to be the intermediate/poor group. Finally, the subjects were divided into two groups: LIPI-good and LIPI-intermediate/poor.

Results. The results shed light on the 110 BTC patients’ LIPI in advanced BTC patients receiving immunotherapy, indicating that the cut-off value of dNLR was 1.74. According to the risk stratification, 38 (34.5%) patients had a good LIPI score, whereas the LIPI score was intermediate/poor in 72 (65.5%). In addition, patients with good LIPI were related to longer progression-free survival (PFS) and overall survival (OS), compared to those with intermediate/poor LIPI (12.17 months vs. 3.17 months; 20.2 months vs. 8.7 months). According to multivariate analysis, the intermediate/poor LIPI group was independently correlated with over 2.3 times greater risk of tumor progression (HR = 2.301; 95% CI, 1.395-3.796; P = 0.001) and over 1.8 times greater risk of death (HR = 1.877; 95% CI, 1.076-3.275; P = 0.027) than the good group. Moreover, the result also revealed that there were significant differences of DCR for patients of the good group and the intermediate/poor group (86.8% vs. 65.3%; P = 0.012).

Conclusion. Finally, this study verifies, for the first time, that LIPI is an independent factor affecting the survival and clinical efficacy of advanced BTC patients receiving immunotherapy. It may be difficult for patients with intermediate/poor LIPI to benefit from immunotherapy.
1. Introduction

In developed countries, biliary tract cancer (BTC) is an uncommon but clinically aggressive cancer, consisting of intrahepatic and extrahepatic cholangiocarcinoma (CCA) and gallbladder cancers [1]. CCA is a malignant tumor, derived from bile duct epithelial cells [2]. The development of Multidisciplinary Treatment (MDT) (i.e., radiotherapist, medical oncologist, and hepatobiliary surgeon) enables CCA patients to obtain the best treatment plan [2]. Recently, the incidence of BTC has increased year by year [3]. Surgery is the main treatment for BTC, but only 20% of BTC patients who are in early stages are candidates [4]. Although BTC is not as infamous as the king of carcinoma, pancreatic cancer, it is still a refractory, high-risk malignant tumor with a high mortality rate. BTC is prone to relapse and metastasis despite early surgical intervention [5]. Chemotherapy is the standard treatment of BTC, but its effect is limited [6]. The established first-line systemic treatment for advanced BTC, albumin-bound paclitaxel combined with gemcitabine and cisplatin (GP), reported that its overall survival (OS) does not exceed one year [7]. Advanced BTC patients did not benefit from targeted therapy reported by some studies [8]. Therefore, immune checkpoint inhibitors (ICIs) have not only become the established first-line systemic treatment for some solid tumors but also bring long-term clinical benefits to patients [9]. ICIs can provide advanced BTC patients durable clinical efficacy with a controllable safety profile, as reported in some studies [10, 11]. Although immunotherapy brings promise to BTC patients, only some patients can benefit from it. Therefore, finding effective and practical biomarkers that can predict the prognosis of immunotherapy is crucial in prolonging life and improving the quality of life for BTC patients. In addition, the combination of multiple indicators is more accurate than a single biomarker in screening people who may benefit from immunotherapy, and it can also provide more specific information in detecting potential subgroups that may benefit from such therapy.

Lung immune prognostic index (LIPI) consists of lactate dehydrogenase (LDH) levels and derived neutrophil-to-lymphocyte (dNLR) ratio. As an effective and economical biomarker, LIPI is indicative of immunotherapeutic efficiency and survival outcomes. Since Mezquita et al. initially reported that LIPI serves as an independent indicator correlated with the outcomes of non-small-cell lung cancer (NSCLC) receiving immunotherapy, numerous researchers validated its value in forecasting the prognosis of other solid tumor patients after immunotherapy [12]. However, whether LIPI is an independent factor affecting the survival and clinical efficacy of advanced BTC patients receiving immunotherapy remains controversial. Thus, this study aimed at exploring the clinical value of LIPI in predicting the prognostic outcomes of advanced BTC patients following ICI treatment.

2. Materials and Methods

2.1. Study Population. Institutional review board approval was acquired to review medical records at the Chinese People’s Liberation Army General Hospital (approval number: S2019-136-01). All the patients involved were diagnosed with BTC at stage IV and received ICI treatment in the Senior Department of Oncology, Chinese PLA General Hospital, from September 2015 to April 2021. The inclusion criteria were set as the following: (1) patients detected with measurable lesions, (2) patients conducted blood routine and blood biochemistry tests within one week before ICI administration, and (3) patients continuously received at least two rounds of ICI treatment. Patients failing to provide imaging data for comparing the efficacy of ICIs before and after treatment were excluded. As a result, a total of 100 patients were considered eligible for this cohort study. Clinical parameters of those BTC patients from their medical records were collected, including sex, age, Eastern Cooperative Oncology Group performance status scores (ECOG PS), smoking history, smoking exposure, history of diabetes, tumor type, liver metastasis, number of metastatic sites, line of treatment with ICIs, ICI agent, immunotherapy scheme, and treatment-related adverse events (TRAEs). Meanwhile, we analyzed their blood routine parameters such as white blood cell count (WBC) and absolute neutrophil count (ANC) 7 days before implementing immunotherapy to obtain dNLR (neutrophil/white blood cell-neutrophil) value as well as blood biochemical data to obtain LDH value.

2.2. Treatment Regimens. The types and doses of ICIs were as follows: (1) sintilimab was injected intravenously 200 mg once every 3 weeks; (2) toripalimab was injected intravenously 240 mg once every 3 weeks; (3) pembrolizumab was injected intravenously at a recommended dose rate of 3 mg/kg, administered once every 3 weeks; (4) nivolumab was injected intravenously at a recommended dosage rate of 2 mg/kg, administered once every 2 weeks. The first imaging evaluation of nivolumab was carried out 2-4 weeks after the 3rd intravenous injection. However, the evaluation of toripalimab, sintilimab, and pembrolizumab was carried out 3-5 weeks after the 2nd intravenous injection. Four treatment methods were used in this study, including ICIs combined with antiangiogenesis therapy, ICIs combined with chemotherapy, and ICIs combined with chemotherapy and antiangiogenic therapy. Antiangiogenic drugs involve lenvatinib (8-12 mg, orally administrated once a day), apatinib (850 mg, orally administrated 30 min after a meal, once a day), and bevacizumab (5 mg/kg body weight, once every two weeks; or 7.5 mg/kg body weight, once every 3 weeks).

The chemotherapy regimens include (1) GS regimen: tigigio (40-60 mg, 2 times a day, orally administrated after breakfast and dinner, 14 days in a row followed by 7 days of interval) and gemcitabine (1250 mg/m^2 on the first day of each cycle, intravenous instillation); (2) GP regimen: cisplatin (75 mg/m^2) and gemcitabine (1250 mg/m^2, intravenous administration on the first day); (3) AS regimen: tigigio (40-60 mg, 2 times a day, orally administrated after breakfast and dinner, 14 days in a row followed by 7 days of interval, use it on the first day of each cycle); (4) GMOX regimen: oxaliplatin (130 mg/m^2) combined with gemcitabine (1250 mg/m^2, intravenously administrated on the first day); (5) AX regimen: capecitabine (1000 mg/m^2, orally administrated twice a day, after breakfast and dinner, 14
consecutive in a row followed by 7 days of interval) conjugated albumin paclitaxel (260 mg/m² intravenous injection the first day of each cycle); and (6) others. All plans were chosen based on the patient’s pathological stage and general health conditions, and all patients signed informed consent for treatment.

2.3. Assessment. For efficacy evaluation, the disease control rate (DCR) and the overall response rate (ORR) is termed as the percentage of patients with complete response (CR), partial response (PR), and stable disease (SD) and the percentage of patients with CR and PR, respectively. For prognosis analysis, OS and progression-free survival (PFS) are the time from the beginning of immunotherapy to death and the time between the onset of ICIs and the progression or death of the tumor, respectively.

2.4. Statistical Analysis. SPSS 26.0 software was used to perform all statistical analyses. Data were summarized as the minimum-maximum range and median for nonnormally distributed continuous variables. Based on the values of α (α = 0.05) and β (β = 0.8), the expected median OS (mOS) of the good LIPI group (mOS = 20 months) and the intermediate/poor LIPI group (mOS = 10 months), we evaluated the number of the sample size of our retrospective cohort study. The specific sample size is shown in attached file 1. Data were reported as percentages and counts for categorical variables. The receiver operating characteristic (ROC) curves were applied to clarify the best cut-off value of dNLR. χ² or Fisher’s exact test was carried out to evaluate the relationship between clinical response and LIPI of BTC patients. The survival curve was depicted by Kaplan-Meier analysis. Logistic regression models and Cox proportional-hazard models were applied to assess the prognostic values of LIPI for DCR and survival, respectively. P values less than 0.05 (P < 0.05) were considered statistically significant.

3. Results

3.1. Baseline Characteristics. A total of 110 advanced BTC patients receiving ICIs were included. The clinical features of the patients were provided in the following (Table 1). The median age of advanced BTC patients receiving ICIs was 59 years old. Patients were predominantly male (60.9%), no history of smoking (67.3%), short history of smoking exposure (smoking exposure history is less than or equal to 30 years in 79.1% of cases), ECOG PS of 0-1 (94.5%), the tumor type of CC (80%), no hepatic metastasis (58.2%), and had fewer organ metastasis (the number of metastatic sites of 0-1 in 64.5% of cases).

3.2. Treatment Characteristics. Of the 110 patients, 34 (30.9%) patients received nivolumab, 11 (10.0%) patients were treated with pembrolizumab, and 65 (59.1%) patients received other immunotherapy drugs; 79 (71.8%) patients were treated with the 1st line ICIs, and 31 (28.2%) patients used ICIs after the 1st line; 73 (66.4%) patients were treated with the combination of immunotherapy and chemotherapy, 9 (8.2%) patients were treated with the combination of immunotherapy and target therapy, 20 (18.2%) patients were treated with monotherapy of ICIs, and 8 (7.3%) patients were treated with the combination of immunotherapy, chemotherapy, and target therapy; 76 (69.1%) patients suffered from TRAEs (Table 1).

3.3. ROC Analysis and Grouping. With dNLR before treatment as the test variable, and the tumor progression rate at the 6th month as the state variable, the ROC curve of immunotherapy effect and dNLR level before treatment was generated. The area under the ROC curve was 0.657, which indicated a statistically significant difference (P = 0.007). The best cut-off value of dNLR was 1.74, and its corresponding sensitivity and specificity were 75% and 60.5%, respectively (Figure 1). The upper limit of LDH normal value was 245 U/L. The advanced BTC patients were divided into the good group and the intermediate/poor group according to the combination of LDH and the cut-off value of dNLR. The high levels of dNLR (≥1.74) and LDH (≥245 U/L) were considered to be two risk factors for the LIPI score system. Based on these two risk factors, patients were categorized into 3 groups based on risk factors: 0 for the good group, 1 for the intermediate group, and 2 for the poor group. Due to the limited number of patients in the poor group, it was integrated into the intermediate group to be the intermediate/poor group. Finally, according to the risk stratification, 38 (34.5%) patients had a good LIPI score, whereas the LIPI score was intermediate/poor in 72 (65.5%).

3.4. The Relationship between LIPI Groups and Response to ICI Treatment. The optimal efficacy of all BTC patients was evaluated in the study, and the results were as follows: 30 patients had progressive disease (PD), 2 patients had CR, 16 patients had PR, and 62 patients had SD. The ORR was 16.4% and DCR was 72.7% (Table 2). The results of logistic regression of disease control rate are summarized in Table 3. The multivariate logistic regression analysis showed that there was a discernable difference of DCR between BTC patients with intermediate/poor and good LIPI (65.3% vs. 86.8%; P = 0.012). The intermediate/poor group was associated with over 5 times greater risk of progressive disease than the LIPI-good group (OR = 5.217; 95% CI, 1.439-18.917). Additionally, we found that patients treated with the combination of immunotherapy and other therapies were associated with over 9 times greater risk of progressive disease than those treated with monotherapy of ICIs (OR = 9.548; 95% CI, 2.654-34.353; P = 0.001). No clear difference of ORR was observed between the intermediate/ poor group and the good group (12.5% vs. 23.7%; P = 0.132).

3.5. The Prognostic Value of LIPI on Univariate Analysis. Among the 110 advanced BTC patients, 66 (60%) patients died before the last follow-up date of June 14, 2021. Patients with a good LIPI were associated with longer PFS and OS, compared to those with intermediate/poor LIPI (12.17 months vs. 3.17 months; 20.2 months vs. 8.7 months) (Figures 2(a) and 2(b) and Table 4). In univariate analysis, patients with a good PS (ECOG PS of 0-1), with good LIPI,
and treated with 1\textsuperscript{st} line ICIs were associated with improved PFS and OS (Table 5).

3.6. The Prognostic Value of LIPI on Multivariate Analysis. After we checked for hazard proportionality, the Cox regression multivariable approach was performed (Supplementary Figures 1a and 1b). Multivariate analysis revealed that patients treated with 1\textsuperscript{st} line ICIs were correlated with over 1.6 times greater risk of tumor progression (HR = 1.677; 95\% CI, 1.055-2.665; \( P = 0.029 \)) and patients that had poor PS (ECOG PS of \( \geq 2 \)) were correlated with over 5 times greater risk of death than patients that had a good PS (ECOG PS of 0-1) (HR = 5.383; 95\% CI, 2.058-14.081; \( P = 0.001 \)). Moreover, patients with the

| Characteristics                                      | Overall (\( n = 110 \)) | The good LIPI (\( n = 38 \)) | The intermediate LIPI (\( n = 56 \)) | The poor LIPI (\( n = 16 \)) |
|------------------------------------------------------|--------------------------|-------------------------------|---------------------------------------|-----------------------------|
| Median age (range), years                            | 59 (24-91)               | 55.5 (24-70)                 | 61 (42-80)                            | 60 (44-91)                  |
| Sex                                                  |                          |                               |                                       |                             |
| Female                                               | 43 (39.1)                | 17 (44.7)                    | 21 (37.5)                             | 5 (36.1)                    |
| Male                                                 | 67 (60.9)                | 21 (55.3)                    | 35 (62.5)                             | 11 (68.8)                   |
| Smoking history                                       |                          |                               |                                       |                             |
| Yes                                                  | 36 (32.7)                | 12 (31.6)                    | 16 (28.6)                             | 8 (50.0)                    |
| No                                                   | 74 (67.3)                | 26 (68.4)                    | 40 (71.4)                             | 8 (50.0)                    |
| Smoking exposure                                      |                          |                               |                                       |                             |
| \( >30 \) packs per year                             | 23 (20.9)                | 10 (26.3)                    | 8 (14.3)                              | 5 (31.3)                    |
| \( \leq 30 \) packs per year                         | 87 (79.1)                | 28 (73.7)                    | 48 (85.7)                             | 11 (68.8)                   |
| History of diabetes                                  |                          |                               |                                       |                             |
| Yes                                                  | 19 (17.3)                | 6 (15.8)                     | 10 (17.9)                             | 3 (18.8)                    |
| No                                                   | 91 (82.7)                | 32 (84.2)                    | 46 (82.1)                             | 13 (81.3)                   |
| Tumor type                                           |                          |                               |                                       |                             |
| CC                                                   | 88 (80.0)                | 32 (84.2)                    | 45 (80.4)                             | 11 (68.8)                   |
| GBC                                                  | 22 (20.0)                | 6 (15.8)                     | 11 (19.6)                             | 5 (31.3)                    |
| Liver metastasis                                     |                          |                               |                                       |                             |
| Present                                              | 46 (41.8)                | 18 (47.4)                    | 18 (32.1)                             | 10 (62.5)                   |
| Absent                                               | 64 (58.2)                | 20 (52.6)                    | 38 (67.9)                             | 6 (37.5)                    |
| Number of metastatic sites                           |                          |                               |                                       |                             |
| \( \geq 2 \)                                         | 39 (35.5)                | 14 (36.8)                    | 17 (30.4)                             | 8 (50.0)                    |
| \( < 2 \)                                            | 71 (64.5)                | 24 (63.2)                    | 39 (69.6)                             | 8 (50.0)                    |
| Lines of immunotherapy                               |                          |                               |                                       |                             |
| \( \geq 2 \)                                         | 31 (28.2)                | 8 (21.1)                     | 17 (69.6)                             | 6 (37.5)                    |
| \( < 2 \)                                            | 79 (71.8)                | 30 (78.9)                    | 39 (30.4)                             | 10 (62.5)                   |
| ECOG PS                                              |                          |                               |                                       |                             |
| \( \geq 2 \)                                         | 6 (5.5)                  | 1 (2.6)                      | 2 (3.6)                               | 3 (18.8)                    |
| 0-1                                                   | 104 (94.5)               | 37 (97.4)                    | 54 (96.4)                             | 13 (81.3)                   |
| PD-1 inhibition agent                                |                          |                               |                                       |                             |
| Nivolumab                                            | 34 (30.9)                | 14 (36.8)                    | 16 (28.6)                             | 4 (25.0)                    |
| Pembrolizumab                                         | 11 (10.0)                | 2 (5.3)                      | 4 (7.1)                               | 5 (31.3)                    |
| Others                                               | 65 (59.1)                | 22 (57.9)                    | 36 (64.3)                             | 7 (43.8)                    |
| ICIs combined with other therapies                   |                          |                               |                                       |                             |
| Monotherapy                                          | 20 (18.2)                | 8 (21.1)                     | 9 (16.1)                              | 3 (18.8)                    |
| Chemotherapy                                         | 73 (66.4)                | 25 (65.8)                    | 37 (66.1)                             | 11 (68.8)                   |
| Target therapy                                       | 9 (8.2)                  | 4 (10.5)                     | 5 (8.9)                               | 0 (0)                       |
| Chemotherapy and target therapy                      | 8 (7.3)                  | 2 (5.3)                      | 5 (8.9)                               | 2 (12.5)                    |
| Treatment-related adverse events                     |                          |                               |                                       |                             |
| Present                                              | 76 (69.1)                | 25 (65.8)                    | 39 (69.6)                             | 12 (75.0)                   |
| Absent                                               | 34 (30.9)                | 13 (34.2)                    | 17 (30.4)                             | 4 (25.0)                    |

CC: GBC: ECOG PS: Eastern Cooperative Oncology Group performance status scores; PD-1: programmed cell death-1; ICIs: immune checkpoint inhibitors.
Figure 1: ROC curve of pretreatment dNLR in assessment of the tumor progression rate at 6th month. ROC: receiver operator characteristic; dNLR: derived neutrophil-to-lymphocyte.

Table 2: Relationship between LIPI groups and response to anti-PD-1 treatment.

| Best overall response | Overall n = 110 | The good LIPI n = 38 | The intermediate/poor LIPI n = 72 | P value |
|-----------------------|----------------|----------------------|-----------------------------------|---------|
| CR                    | 2 (1.8)        | 1 (2.6)              | 1 (1.4)                           | 1       |
| PR                    | 16 (14.5)      | 8 (21.1)             | 8 (11.1)                          | 0.160   |
| SD                    | 62 (56.4)      | 24 (63.2)            | 38 (52.8)                         | 0.297   |
| PD                    | 30 (27.3)      | 5 (13.2)             | 25 (34.7)                         | 0.016*  |
| Objective response    | 18 (16.4)      | 9 (23.7)             | 9 (12.5)                          | 0.132   |
| Disease control rate  | 80 (72.7)      | 33 (86.8)            | 47 (65.3)                         | 0.016*  |

LIPI: lung immune prognostic index; PD-1: programmed cell death-1; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.

Table 3: Logistic regression of disease control rate.

| Characteristics                  | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | OR (95% CI)         | P         | OR (95% CI)         | P         |
| Lines of immunotherapy          |                     |           |                     |           |
| <2                               | 1 [ref.]            |           | 1 [ref.]            |           |
| ≥2                               | 0.250 (0.102-0.616) | 0.003*    | 0.401 (0.1441.120) | 0.081     |
| Combined with other therapies    |                     |           |                     |           |
| No                               | 1 [ref.]            | <0.001*   | 1 [ref.]            | 0.001*    |
| Yes                              | 7.975 (2.764-23.010)|           | 9.548 (2.654-34.353)|           |
| LIPI                             |                     |           |                     |           |
| The good                         | 1 [ref.]            |           | 1 [ref.]            |           |
| The intermediate/poor            | 3.511 (1.218-7.134) | 0.002*    | 5.217 (1.439-18.917)| 0.012*    |

LIPI: lung immune prognostic index.
intermediate/poor LIPI were associated with more than twice the risk of tumor progression (HR = 2.301; 95% CI, 1.395-3.796; \(P < 0.001\)) and more than 1.8-fold increased risk of death than the good LIPI (HR = 1.877; 95% CI, 1.076-3.275; \(P = 0.027\)), respectively.

3.7. Association of the LIPI with Outcomes in Lines of Immunotherapy of 1 or in Subsequent Lines of Immunotherapy (≥2): Subgroup Analysis. Multivariate analysis revealed that patients treated with the 1st line ICIs were independently correlated with improved OS and PFS. Our

![Figure 2: PFS (a) and OS (b) according to LIPI groups of patients with advanced BTC treated with the ICIs. PFS: progression-free survival; OS: overall survival; LIPI: lung immune prognostic index; BTC: biliary tract cancer; ICIs: immune checkpoint inhibitors.](image)
Table 4: Efficacy and prognosis based on the LIPI groups.

| LIPI classification | Response rate (n, %) | DCR (n, %) | OR (95% CI) | OS (months) | Median HR (95% CI) | PFS (months) | Median HR (95% CI) |
|---------------------|---------------------|------------|-------------|-------------|---------------------|--------------|-------------------|
| The good (n = 38)   | 33 (86.8)           | 1 [reference] | 20.2 (0.00-43.40) | 1 [reference] | 12.17 (4.29-20.05) | 1 [reference] |
| The intermediate/poor (n = 72) | 47 (65.3) | 5.217 (1.439-18.917) | 8.7 (6.59-10.81) | 1.877 (1.076-3.275) | 3.17 (1.77-4.56) | 2.301 (1.395-3.796) |
| P value             | 0.012*              | 0.027*     | 0.001*      |             |                     |              |                   |

PFS: progression-free survival; OS: overall survival; LIPI: lung immune prognostic index.

Table 5: Univariate and multivariate analyses of factors associated with OS and PFS.

(a)

| Patient characteristics | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
|                         | OS                  |                       |
|                         | HR (95% CI)         | P                     | HR (95% CI)         | P                     |
| ECOG performance status |                     |                       |
| 0-1                     | 1 [ref.]            |                       | 1 [ref.]            |                       |
| ≥2                      | 5.473 (2.099-14.266) | 0.001*               | 5.383 (2.058-14.081) | 0.001*               |
| Lines of immunotherapy  |                     |                       |
| <2                      | 1 [ref.]            |                       | 1 [ref.]            |                       |
| ≥2                      | 1.678 (1.021-2.758)  | 0.041*               | 1.523 (0.919-2.526)  | 0.103                |
| LIPI                    |                     |                       |
| The good                | 1 [ref.]            |                       | 1 [ref.]            |                       |
| The intermediate/poor   | 1.892 (1.085-3.299)  | 0.024*               | 1.877 (1.076-3.275)  | 0.027*               |

(b)

| Patient characteristics | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
|                         | PFS                 |                       |
|                         | HR (95% CI)         | P                     | HR (95% CI)         | P                     |
| Lines of immunotherapy  |                     |                       |
| ≥2                      | 1 [ref.]            |                       | 1 [ref.]            |                       |
| <2                      | 1.963 (1.247-3.091)  | 0.004*               | 1.677 (1.055-2.665)  | 0.029*               |
| ECOG performance status |                     |                       |
| ≥2                      | 2.558 (1.022-6.404)  | 0.045*               | 2.348 (0.927-5.946)  | 0.072                |
| 0-1                     | 1 [ref.]            |                       | 1 [ref.]            |                       |
| LIPI                    |                     |                       |
| The good                | 1 [ref.]            |                       | 1 [ref.]            |                       |
| The intermediate/poor   | 2.524 (1.540-4.137)  | <0.001*              | 2.301 (1.395-3.796)  | 0.001*               |

PFS: progression-free survival; OS: overall survival; LIPI: lung immune prognostic index; ECOG PS: Eastern Cooperative Oncology Group performance status scores.

Table 6: Univariate analyses of LIPI associated with OS and PFS of BTC patients treated with 1st line ICIs.

| LIPI classification | OS (months) | Patients treated with the 1st line ICIs | PFS (months) |
|---------------------|-------------|----------------------------------------|--------------|
|                     | Median     | HR (95% CI) | Median | HR (95% CI) |
| The good (n = 30)   | 34.43      | 1 [reference] | 12.93 | 1 [reference] |
| The intermediate/poor (n = 49) | 15.8   | 2.147 (1.061-4.344) | 5.87   | 3.006 (1.601-5.642) |
| P value             | 0.03       | <0.001      |        |             |

PFS: progression-free survival; OS: overall survival; LIPI: lung immune prognostic index; BTC: biliary tract cancer; ICIs: immune checkpoint inhibitors.
study then conducted a subgroup analysis based on different lines of immunotherapy. Univariate analyses of the association of LIPI with outcomes in lines of immunotherapy of 1 are shown in Table 6. For the 79 patients treated with 1st line ICIs, 49 patients were in the intermediate/poor LIPI group and 30 patients were in the good group. Patients with good LIPI had improved PFS and OS than those with intermediate/poor LIPI (12.93 months vs. 5.87 months; 34.43 months vs. 15.8 months) (Figures 3(a) and 3(b)). The intermediate/poor LIPI was correlated with over 2.1 times greater risk of death (HR = 2.147; 95% CI, 1.061-4.344; P = 0.03) and over 3 times greater risk of tumor progression (HR = 3.006; 95% CI, 1.601-5.642; P < 0.001) than the good LIPI. Univariate analyses of the association of LIPI with outcomes in subsequent lines of immunotherapy (≥2) are shown in Table 7. For the 31 patients treated with ICIs in subsequent lines, 23 patients were in the intermediate/poor LIPI group and 8 patients were in the good group. Patients with good and
intermediate/poor LIPI did not show a clear difference in PFS and OS (3.9 months vs. 3.13 months; 8.7 months vs. 7.97 months; $P = 0.345; P = 0.778$) (Figures 4(a) and 4(b)).

4. Discussion

The usage of immunotherapy in the field of tumor treatment has been increasing annually worldwide, which has been proven to be widely used in a variety of solid tumors. However, immunotherapy drugs are expensive and prone to drug resistance and the occurrence of hyperprogressive disease (HPD). Therefore, looking for predictive indicators in the population that could benefit from immunotherapy could help lead to more precise and efficient immunotherapy treatment. The most widely studied markers for predicting the efficacy of immunotherapy are programmed death ligand-1 (PD-L1) expression, tumor mutational burden (TMB), and microsatellite steady-state (MSI). At present, the best biomarker for screening beneficial populations is PD-L1. Nevertheless, its screening capabilities are not consistent. The predictive value of PD-L1 on the efficacy of immunotherapy varies in different tumor types. It has predictive value for the prognosis of NSCLC, melanoma, and renal cell carcinoma, but it is controversial for colorectal cancer [13]. The optimum cut-off value of PD-L1 positive also varies in different studies [14]. PD-L1 expression in cells is not a fixed value, as it can be influenced by the collection time, the collection location, and the treatment plan [15]. TMB has emerged as an independent biomarker for immunotherapy. However, Horn et al. found that blood TMB (bTMB) is not associated with immune efficacy [16]. In addition, its application in clinical practice also has certain limitations. The TMB test relies on gene sequencing; thus, the cost is higher than the PD-L1 test. The storage time of specimens also has a certain influence on the judgment of TMB test results [16]. As a commonly used auxiliary diagnostic index, LDH level is an important and independent factor in predicting the prognosis of patients with malignant tumors receiving ICIs as shown by some studies [17]. A study on the use of ICI treatment for melanoma showed that high levels of LDH were associated with poor prognosis [17]. It is well established that immune performance and inflammatory response profoundly impact the long-term outcomes of cancer patients. Neutrophils, one type of the most vital and abundant leukocytes in the blood, are the first-line defense to protect the host from tissue damage and infection [18]. The number, subsets, and molecular characteristics of leukocytes have been analyzed in cancer patients as prognostic and predictive biomarkers for several decades [19]. Notoriously, the neutrophil-to-lymphocyte ratio has been proposed as an inflammatory biomarker elevated in patients with more advanced or aggressive diseases [19]. A blood-based liquid biopsy can capture circulating tumor cells and leukocytes, as well as circulating tumor-derived nucleic acids [19]. For the reason that a practical example in the frame of this thinking might be considering, within the field of inflammatory biomarkers, the integration with liquid biopsy and noninvasive tool [19]. Tumor-infiltrating lymphocytes are an indicator of the immune status in the tumor microenvironment, and the neutrophils are immunosuppressive. The reactive oxygen species released by neutrophil can damage DNA, which is related to the occurrence and development of tumors [20]. The neutrophil-to-lymphocyte ratio (NLR) can comprehensively reflect the immune status and inflammation of the tumor patients [21]. Existing studies show that high levels of NLR were associated with poor prognosis of lung cancer patients after immunotherapy [22]. dNLR is defined as the ratio between the pretreatment neutrophil and white blood cell minus neutrophil. The dNLR can reflect changes in the body’s immune system, so it is more meaningful than NLR [12]. Regarding the criteria for judging the level of dNLR, large foreign clinical studies have selected 3 as the cut-off value [12]. Because of ethnic physiological differences, there were fewer patients with dNLR ≥3 in this study. If the cut-off value was set to be 3, there will be a big difference between the two groups of patients. Therefore, the cut-off value was determined by the ROC curve. The ROC curve was generated using the tumor progression status as the status variable and the dNLR level before treatment at the 6th month of immunotherapy as the test variable. Finally, 1.74 was selected as the cut-off value of dNLR. Mezquita et al. and Kazandjian et al. found that in different treatment methods, LIPI was related to patients with PFS and OS [12, 23]. The high levels of dNLR (≥3) and LDH (≥245 U/L) were considered to be two risk factors for the LIPI score system in our study. Based on these two risk factors, BTC patients were categorized into 3 groups: the risk factor number for the “good” group was 0, for the “intermediate” group was 1, and for the “poor” group was 2 [12, 20, 24]. However, high level of dNLR (≥1.74) was considered a risk factor in our study. Some studies revealed that LIPI could be used as an effective and economical biomarker to predict immunotherapeutic efficiency and survival outcomes in gastric cancer, melanoma, renal cell carcinoma, and

---

**Table 7: Univariate analyses of LIPI associated with OS and PFS of BTC patients treated with ICIs in subsequent lines.**

| LIPI classification | OS (months) | PFS (months) | Patients treated with ICIs in subsequent lines |
|---------------------|-------------|--------------|-----------------------------------------------|
| The good (n = 8)    | Median      | HR (95% CI)  | Median                                      |
|                     | 34.43       | 1 [reference]| 12.93                                       |
| The intermediate/poor (n = 23) | 15.8       | 1.140 (0.457-2.844) | 5.87                                       |
|                     | 0.778       |              | 1.505 (0.638-3.552)                        |
| $P$ value           |             |              | 0.345                                        |

PFS: progression-free survival; OS: overall survival; LIPI: lung immune prognostic index; BTC: biliary tract cancer; ICIs: immune checkpoint inhibitors.
advanced hepatocellular carcinoma patients with ICIs [24–27]. The study first demonstrated the association of LIPI and clinical benefit, OS, and PFS in advanced BTC patients treated with ICIs. Multivariate analysis revealed that the good group was correlated independently with longer OS and PFS. The prognostic value of LIPI in advanced BTC was in close agreement with that of previous studies in some solid tumors [24–27]. Additionally, Chen et al., Benitez et al., and Hou et al. noticed that patients with a good PS (ECOG PS of 0-1) were also independently associated with PFS, OS, and DCR [24–27]. However, patients who had a poor PS (ECOG PS of ≥2) were independently associated with OS (HR = 5.383; 95% CI, 2.058-14.081; P = 0.001), not with PFS and DCR in

Figure 4: PFS (a) and OS (b) according to LIPI groups of patients with advanced BTC treated with the ICIs in subsequent lines. PFS: progression-free survival; OS: overall survival; LIPI: lung immune prognostic index; BTC: biliary tract cancer; ICIs: immune checkpoint inhibitors.
our study. Chen et al. found that patients treated with the combination of immunotherapy and targeted therapy were independently associated with PFS (HR = 0.58; 95% CI, 0.32-0.94; *P* = 0.028) [25]. Furthermore, Hou et al. noticed that patients treated with the combination of immunotherapy and other therapies were associated with longer OS, with HRs of 0.58 (95% CI, 0.37-0.93; *P* = 0.024), and PFS, with HRs of 0.49 (95% CI, 0.30-0.81; *P* = 0.005) [27]. Nevertheless, we found that patients treated with the combination of immunotherapy and other therapies were associated with an over 9 times greater risk of tumor progression than those that used monotherapy (OR = 9.548; 95% CI, 2.654-34.353; *P* = 0.001). This result disagrees with the conclusion of Chen et al. and Hou et al. Mezquita et al. noticed that lines of immunotherapy were irrelevant to OS and PFS [12]. However, we found that patients treated with 1st line ICIs were correlated with over 1.6 times greater risk of tumor progression (HR = 1.677; 95% CI, 1.055-2.665; *P* = 0.029). In addition, we found that two of the enrolled patients reached CR in the efficacy evaluation. Their common features include the following: (1) they are all women older than 58 years old, (2) they have liver metastases, and (3) they all use nivolumab combined with GP in the first line. Therefore, we speculate that older female patients may get better clinical benefits from nivolumab combined with GP in the first line. In recent years, peripheral blood inflammatory complex indexes such as NLR, platelet-lymphocyte ratio (PLR), dNLR, and hemoglobin (Hb) levels have demonstrated a potential prognostic biomarker for some solid tumors receiving ICIs [11, 28-30]. However, the mechanism of the correlation between these peripheral blood inflammatory complex indexes and the tumor prognosis is still unclear. Some studies have found that this was probably due to the tumor-immune microenvironment of patients [31, 32]. Patients with higher NLR typically have shorter OS and PFS, which may be related to the higher level of neutrophil-dependent inflammation in the immune microenvironment. dNLR can reflect the changes in the body’s immune system as the increased dNLR is often caused by an increment of neutrophils or a decrease of lymphocytes. Increased number of neutrophils in the peripheral blood can promote tumor metastasis and growth by releasing inflammatory mediators [33]. On the other hand, decreased lymphocyte count will weaken the body’s immune surveillance of tumor cells, which is conducive to tumor proliferation and metastasis. As a result, increased dNLR often indicates a poor prognosis in a variety of malignant tumors (pancreatic cancer, lymphoma, etc.). LDH is also a classic inflammatory marker and a manifestation of tumor burden in cancer patients. High levels of LDH are significantly correlated with worse PFS and OS. Alternatively, if it is not associated with other powerful clinical indicators (such as platelet count or NLR), the LDH level alone does not possess an independent prognostic significance [34, 35]. Therefore, the lower LIPI score the tumor patients have (i.e., the higher dNLR and LDH they get), the worse their prognosis will be. The reason of this phenomenon needs further study. LIPI, a practical and convenient prognostic marker, can be tested in almost all hospitals. It is expected to become a supplementary biomarker for advanced BTC with ICIs.

In the current study, some potential limitations should be noted. First, the primary limitation of this study is the small number of participants (*N* = 110). Due to the time and geographic limitations, this research investigated participants with a mixed population of intrahepatic advanced BTC, extrahepatic advanced BTC, and gallbladder cancer only from the same hospital. Additionally, a lack of comparison of LIPI score among the three cancers is another limitation which would reduce the reliability of the data analysis. Further study, therefore, is necessary to be conducted in advanced BTC treated with anti-PD-1 therapy for the study precision and reliability.

### 5. Conclusion

In conclusion, this study demonstrated that LIPI is independently correlated with the survival and clinical efficacy of advanced BTC patients receiving ICIs. However, the possibility of using LIPI as an effective and economic prognostic biomarker to selected patients, those who are best suited to receiving ICIs, needs further investigation in a larger prospective study.

### Abbreviations

- **BTC**: Biliary tract cancer
- **CCA**: Cholangiocarcinoma
- **MDT**: Multidisciplinary Treatment
- **GP**: Gemcitabine and cisplatin
- **OS**: Overall survival
- **ICIs**: Immune checkpoint inhibitors
- **LIPI**: Lung immune prognostic index
- **LDH**: Lactate dehydrogenase
- **dNLR**: Derived neutrophil-to-lymphocyte ratio
- **NSCLC**: Non-small-cell lung cancer
- **ECOG PS**: Eastern Cooperative Oncology Group performance status scores
- **TRAES**: Treatment-related adverse events
- **WBC**: White blood cell count
- **ANC**: Absolute neutrophil count
- **ALC**: Absolute lymphocyte count
- **DCR**: Disease control rate
- **ORR**: Overall response rate
- **CR**: Complete response
- **PR**: Partial response
- **SD**: Stable disease
- **PFS**: Progression-free survival
- **ROC**: Receiver operator characteristic
- **PD**: Progressive disease
- **HPD**: Hyperprogressive disease
- **PD-L1**: Programmed death ligand-1
- **TMB**: Tumor mutational burden
- **MSI**: Microsatellite steady-state
- **bTMB**: Blood TMB
- **TAN**: Tumor-associated neutrophils
- **NLR**: Neutrophil-to-lymphocyte ratio
PLR: Platelet-lymphocyte ratio  
Hb: Hemoglobin.

Data Availability

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethical Approval

This study was approved by the Ethics Committee of Chinese PLA General Hospital, and was conducted according to the principles of the Declaration of Helsinki.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Authors’ Contributions

YP was in charge of writing and analysis. GD and NQ provided the guide and idea. HS, RJ, GD, HY, MF, GM, SC, NZ, and YS contributed to the analysis. All authors contributed to the article and approved the submitted version.

Acknowledgments

The authors gratefully acknowledge the advice and insights of Dr. Guanghui Dai, whose work is supported (or supported in part) by the Senior Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital; and Niansong Qian whose work is supported (or supported in part) by the Hainan Medical Center, Chinese PLA General Hospital.

Supplementary Materials

Supplementary 1: attached file 1A: sample calculation. Supplementary 2: Figure 1: PFS (a) and OS (b) according to LIPI groups of patients with advanced BTC treated with the ICI. (Supplementary Materials)

References

[1] S. Nara, M. Esaki, D. Ban et al., “Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials,” Japanese Journal of Clinical Oncology, vol. 50, no. 12, pp. 1353–1363, 2020.
[2] G. Brandi, M. Venturi, M. A. Pantaleo et al., “Cholangiocarcinoma: current opinion on clinical practice diagnostic and therapeutic algorithms: a review of the literature and a long-standing experience of a referral center,” Digestive and Liver Disease, vol. 48, no. 3, pp. 231–241, 2016.
[3] J. N. Primrose, R. P. Fox, D. H. Palmer et al., “Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study,” The Lancet Oncology, vol. 20, no. 5, pp. 663–673, 2019.
[4] A. Lamarca, J. Edeline, M. G. McNamara et al., “Current standards and future perspectives in adjuvant treatment for biliary tract cancers,” Cancer Treatment Reviews, vol. 84, article 101936, 2020.
[5] D. A. Sanoyan, M. G. McNamara, A. Lamarca, and J. W. Valle, “Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives,” Current Opinion in Oncology, vol. 32, no. 4, pp. 364–369, 2020.
[6] J. Weigt and P. Malfertheiner, “Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer,” Expert Review of Gastroenterology & Hepatology, vol. 4, no. 4, pp. 395–397, 2010.
[7] I. Park, J. L. Lee, M. H. Ryu et al., “Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy,” Cancer, vol. 115, no. 18, pp. 4148–4155, 2009.
[8] M. Moehler, A. Maderer, C. Schimanski et al., “Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme,” European Journal of Cancer, vol. 50, no. 18, pp. 3125–3135, 2014.
[9] E. W. Cohen, D. Soulères, C. Le Tourneau et al., “Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study,” vol. 393, no. 10167, pp. 156–167, 2019.
[10] R. D. Kim, V. Chung, O. B. Alese et al., “A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer,” JAMA Oncology, vol. 6, no. 6, pp. 888–894, 2020.
[11] M. Gou, Y. Zhang, T. Liu et al., “PD-1 inhibitors could improve the efficacy of chemotherapy as first-line treatment in biliary tract cancers: a propensity score matching based analysis,” Frontiers in Oncology, vol. 11, 2021.
[12] L. Mezquita, E. Auclin, R. Ferrara et al., “Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non–small cell lung cancer,” JAMA Oncology, vol. 4, no. 3, pp. 351–357, 2018.
[13] D. T. Le, J. N. Uram, H. Wang et al., “PD-1 blockade in tumors with mismatch-repair deficiency,” The New England Journal of Medicine, vol. 372, no. 26, pp. 2509–2520, 2015.
[14] C. Grigg and N. A. Rizvi, “PD-L1 biomarker testing for non–small cell lung cancer: truth or fiction?,” Journal for Immunotherapy of Cancer, vol. 4, no. 1, p. 48, 2016.
[15] J. M. Taube, “Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L blockade,” Oncoimmunology, vol. 3, no. 11, article e963413, 2014.
[16] L. Horn, A. S. Mansfield, A. Szczesna et al., “First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer,” The New England Journal of Medicine, vol. 379, no. 23, pp. 2220–2229, 2018.
[17] B. Weide, A. Martens, J. C. Hassel et al., “Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab,” Clinical Cancer Research, vol. 22, no. 22, pp. 5487–5496, 2016.
[18] T. Németh, M. Sperandio, and A. Mócsei, “Neutrophils as emerging therapeutic targets,” Nature Reviews. Drug Discovery, vol. 19, no. 4, pp. 253–275, 2020.
[19] M. Russano, A. Napolitano, G. Ribelli et al., “Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples,” Journal of Experimental & Clinical Cancer Research, vol. 39, no. 1, 2020.
H. L. Wright, M. Lyon, E. A. Chapman, R. J. Moots, and S. W. Edwards, “Rheumatoid arthritis synovial fluid neutrophils drive inflammation through production of chemokines, reactive oxygen species, and neutrophil extracellular traps,” *Frontiers in Immunology*, vol. 11, 2021.

C. Guo, P. Ding, C. Xie et al., “Potential application of the oxidative nucleic acid damage biomarkers in detection of diseases,” *Oncotarget*, vol. 8, no. 43, pp. 75767–75777, 2017.

M. Nakao, H. Muramatsu, Y. Kagawa et al., “Immunological status may predict response to nivolumab in non–small cell lung cancer without driver mutations,” *Anticancer Research*, vol. 37, no. 7, pp. 3781–3786, 2017.

D. Kazandjian, Y. Gong, P. Keegan, R. Pazdur, and G. M. Blumenthal, “Prognostic value of the lung immune prognostic index for patients treated for metastatic non–small cell lung cancer,” *JAMA Oncology*, vol. 5, no. 10, pp. 1481–1485, 2019.

D. E. Meyers, I. Stukalin, I. A. Vallerand et al., “The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors,” *Cancers*, vol. 11, no. 11, p. 1713, 2019.

S. Chen, Z. Huang, W. Jia et al., “Association of the pretreatment lung immune prognostic index with survival outcomes in advanced hepatocellular carcinoma patients treated with PD-1 inhibitors,” *Journal of Hepatocellular Carcinoma*, vol. 7, no. 7, pp. 289–299, 2020.

J. C. Benitez, G. Recondo, E. Rassy, and L. Mezquita, “The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors,” *The Quarterly Journal of Nuclear Medicine and Molecular Imaging*, vol. 64, no. 2, pp. 162–174, 2020.

B. Hou, P. Wang, T. Liu et al., “Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors,” *Clinics and Research in Hepatology and Gastroenterology*, vol. 45, no. 5, article 101748, 2021.

S. Dharmapuri, U. Özbek, J. Y. Lin et al., “Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy,” *Cancer Medicine*, vol. 9, no. 14, pp. 4962–4970, 2020.

R. D. Seban, J. B. Assié, E. Giroux-Leprieur et al., “Association of the metabolic score using baseline FDG-PET/CT and dNLR with immunotherapy outcomes in advanced NSCLC patients treated with first-line pembrolizumab,” *Cancers*, vol. 12, no. 8, p. 2234, 2020.

Y. Pan, Z. Wang, and G. Dai, “Predictive value of albumin and neutrophil combined prognostic grade in advanced gastric cancer patients treated with anti-PD-1 therapy,” *Research Square*, vol. 11, no. 11, 2021.

F. Balkwill and A. Mantovani, "Inflammation and cancer: back to Virchow?,” *Lancet*, vol. 357, no. 9255, pp. 539–545, 2001.

L. M. Coussens and Z. Werb, "Inflammation and cancer," *Nature*, vol. 420, no. 6917, pp. 860–867, 2002.

S. Kumar and M. Dikshit, "Metabolic insight of neutrophils in health and disease," *Frontiers in Immunology*, vol. 10, no. 1, p. 2099, 2019.